Emergent BioSolutions Inc EBS
News
Emergent BioSolutions Gets Anthrax Vaccine Contract Modification Up to $22.3M
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Emergent BioSolutions Gets $54 Million Contract Award for Smallpox Preparedness
Emergent BioSolutions Gets FDA Greenlight for Multipacks of Narcan
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading — Update
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading


